^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    FLT3 inhibitor

    Related drugs:
    6d
    Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment (clinicaltrials.gov)
    P1, N=12, Recruiting, Daiichi Sankyo | Trial completion date: Mar 2026 --> Oct 2026 | Trial primary completion date: Mar 2026 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Vanflyta (quizartinib)
    7d
    Computational validation of inhibitors for human phosphatidylinositol 4-phosphate 5-kinase-type 1 α protein implicated in cancer. (PubMed, J Biomol Struct Dyn)
    Four protein kinase inhibitors, R547, GDC-0879, JNJ-7706621 and ABT-869 were found to bind hPIP5K1α via a stable complex formation. The hit molecules display favorable ADME properties and are predicted to be non-carcinogenic. The hit molecules in particular R547, have better binding free energies compared to reference molecule, ISA-2011B.
    Journal
    |
    PIP5K1A (Phosphatidylinositol-4-Phosphate 5-Kinase Type 1 Alpha)
    |
    GDC 0879 • linifanib (ABT-869) • R-547
    7d
    MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=69, Recruiting, Emory University | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • MRX2843
    7d
    QuANTUM-WILD: Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML (clinicaltrials.gov)
    P3, N=700, Recruiting, Daiichi Sankyo | N=283 --> 700
    Enrollment change
    |
    cytarabine • Vanflyta (quizartinib) • daunorubicin • idarubicin hydrochloride
    11d
    A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=18, Recruiting, Memorial Sloan Kettering Cancer Center | N=36 --> 18
    Enrollment change
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 mutation • IDH2 mutation • FLT3 mutation
    |
    Xospata (gilteritinib) • Tibsovo (ivosidenib) • Idhifa (enasidenib)
    11d
    miR-500a-3p negatively regulates SOCS2 and participates in the proliferation, glycolysis, and apoptosis of HCC cells via the JAK2/STAT5 pathway. (PubMed, J Appl Biomed)
    This study reveals that miR-500a-3p promotes proliferation and glycolysis while inhibiting apoptosis of HCC cells by negatively regulating SOCS2 and activating the JAK2/STAT5 pathway.
    Journal
    |
    SOCS2 (Suppressor Of Cytokine Signaling 2)
    |
    Inrebic (fedratinib)
    11d
    Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1/2, N=160, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Vonjo (pacritinib)
    13d
    Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial. (PubMed, Ther Adv Hematol)
    The FMF-02 trial is the first randomized phase IIb study directly comparing the novel inhibitor FM against RUX. Its findings are expected to generate pivotal evidence regarding whether FM offers superior or differentiated clinical benefits, thereby informing its potential as a frontline therapy for intermediate- to high-risk MF and guiding the design of future phase III studies.
    P2b data • Journal
    |
    JAK2 (Janus kinase 2) • CDK6 (Cyclin-dependent kinase 6)
    |
    Jakafi (ruxolitinib) • flonoltinib
    13d
    VAG-3+7-G: VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China | Initiation date: Jan 2026 --> Apr 2026
    Trial initiation date
    |
    FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2)
    |
    FLT3-ITD mutation • FLT3-TKD mutation
    |
    Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine • daunorubicin • idarubicin hydrochloride
    14d
    FLT3-ITD scaffolds PKCι-STAT1 to drive noncanonical S727 phosphorylation and CD276-driven CD8+ T-cell exhaustion in AML. (PubMed, Blood)
    In patient-derived xenograft models, co-treatment with FLT3i (quizartinib) and CD276-targeting agents led to 72.9%-80.4% tumor burden reduction and enhanced CD8+ T cell function, outperforming quizartinib monotherapy. These findings define a scaffolded PKCι-pS727-STAT1 signaling axis that promotes immune evasion in FLT3-ITD AML, supporting combined FLT3 and CD276 targeting as a promising translational strategy in this aggressive leukemia subtype.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD276 (CD276 Molecule) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    FLT3-ITD mutation
    |
    Vanflyta (quizartinib)
    14d
    Autophagy inhibition potentiates the antileukemic effect of FLT3 inhibitors and overcomes resistance in FLT3-ITD acute myeloid leukemia. (PubMed, Cell Death Discov)
    In FLT3-ITD AML cell lines (MOLM13 and MV4-11), treatment with first- and second-generation FLT3i (midostaurin and quizartinib, respectively) induced autophagy. The combination of quizartinib and chloroquine demonstrated a synergistic effect in MV4-11QR cells and this effect was associated with greater inhibition of the FLT3 receptor compared to the monotherapies. Therefore, combining FLT3i with autophagy inhibition enhances the FLT3i antileukemic efficacy and overcomes pharmacological resistance.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • ATG5 (Autophagy Related 5) • ATG7 (Autophagy Related 7) • RFC4 (Replication Factor C Subunit 4)
    |
    FLT3-ITD mutation
    |
    midostaurin • Vanflyta (quizartinib) • chloroquine phosphate
    20d
    KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Beijing Konruns Pharmaceutical Co., Ltd.
    New P2 trial
    |
    cisplatin • paclitaxel • Loqtorzi (toripalimab-tpzi) • KC1036